• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2010 年妇科癌症国际协作组（GCIG）卵巢癌临床试验共识声明：第四届卵巢癌共识会议报告。

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

机构信息

NCIC-CTG, Canada.

出版信息

Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568.

DOI:10.1097/IGC.0b013e31821b2568
PMID:21543936
Abstract

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference.

摘要

2010 年妇科癌症国际协作组（GCIG）卵巢癌临床试验共识声明。本报告提供了第四次卵巢癌共识会议的结果。

相似文献

1
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.2010 年妇科癌症国际协作组（GCIG）卵巢癌临床试验共识声明：第四届卵巢癌共识会议报告。
Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568.
2
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.妇科癌症协作组在提高卵巢癌临床试验水平方面的全球影响。
Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446.
3
American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track.美国临床肿瘤学会 2012 年年会：妇科肿瘤学专场亮点。
Int J Gynecol Cancer. 2012 Nov;22(9):1634-9. doi: 10.1097/IGC.0b013e318270febe.
4
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).妇科肿瘤研究组（GCIG）关于低恶性潜能卵巢肿瘤（交界性卵巢肿瘤）的共识综述。
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282.
5
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.妇科肿瘤协作组（GCIG）共识综述：子宫和卵巢平滑肌肉瘤
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261.
6
First-line therapy in ovarian cancer trials.卵巢癌临床试验中的一线治疗。
Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d.
7
Clinical trials in recurrent ovarian cancer.复发性卵巢癌的临床试验。
Int J Gynecol Cancer. 2011 May;21(4):771-5. doi: 10.1097/IGC.0b013e31821bb8aa.
8
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.妇科癌症协作组内的临床试验协调：第五届卵巢癌共识会议的共识和未满足需求。
Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449.
9
The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report.优先宫颈癌试验的发展：妇科癌症协作组报告。
Int J Gynecol Cancer. 2010 Aug;20(6):1092-100. doi: 10.1111/IGC.0b013e3181e730aa.
10
When Impact Multiplies: Defining Trials and Insights from the 2025 Society of Gynecologic Oncology Annual Meeting.当影响力成倍增长：定义试验及来自2025年妇科肿瘤学会年会的见解
Int J Gynecol Cancer. 2025 Jul;35(7):101895. doi: 10.1016/j.ijgc.2025.101895. Epub 2025 Apr 22.

引用本文的文献

1
The Concept of "Platinum Sensitivity" in Endometrial Cancer.子宫内膜癌中“铂敏感性”的概念
Cancers (Basel). 2025 Aug 2;17(15):2557. doi: 10.3390/cancers17152557.
2
CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study.基于CT的放射组学模型预测上皮性卵巢癌铂敏感性：一项多中心研究。
Cancer Imaging. 2025 Jul 3;25(1):85. doi: 10.1186/s40644-025-00906-9.
3
Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer.转变治疗模式：聚焦高级别浆液性卵巢癌的个性化医疗。
CA Cancer J Clin. 2025 Apr 19. doi: 10.3322/caac.70008.
4
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial.在复发性铂耐药卵巢癌随机临床试验中，化疗药物识别引导治疗提高客观缓解率。
NPJ Precis Oncol. 2025 Mar 25;9(1):86. doi: 10.1038/s41698-025-00874-0.
5
Residual Tumour at CT Scan Based on Radiologic Peritoneal Carcinomatosis Index After Optimal Cytoreduction in Advanced Ovarian Cancer: A True Prognostic Factor.基于放射学腹膜癌指数的CT扫描在晚期卵巢癌最佳肿瘤细胞减灭术后的残留肿瘤：一个真正的预后因素
Cancers (Basel). 2025 Feb 22;17(5):746. doi: 10.3390/cancers17050746.
6
Incisional Hernia in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Single-Center Retrospective Study.晚期卵巢癌细胞减灭术中切口疝：一项单中心回顾性研究
Cancers (Basel). 2025 Jan 27;17(3):418. doi: 10.3390/cancers17030418.
7
Methylstat sensitizes ovarian cancer cells to PARP-inhibition by targeting the histone demethylases JMJD1B/C.甲磺司特通过靶向组蛋白去甲基化酶JMJD1B/C使卵巢癌细胞对PARP抑制敏感。
Cancer Gene Ther. 2025 Mar;32(3):286-296. doi: 10.1038/s41417-025-00874-z. Epub 2025 Feb 6.
8
Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters.高级别浆液性输卵管卵巢癌中的三级淋巴结构：解剖部位至关重要。
Cancer Immunol Immunother. 2025 Jan 3;74(2):56. doi: 10.1007/s00262-024-03911-2.
9
Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis.法乐图单抗治疗卵巢癌的疗效与安全性：一项系统评价与单臂荟萃分析
Cureus. 2024 Nov 12;16(11):e73503. doi: 10.7759/cureus.73503. eCollection 2024 Nov.
10
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.靶向放射性药物：卵巢癌研究不足的策略。
Theranostics. 2024 Sep 30;14(16):6281-6300. doi: 10.7150/thno.99782. eCollection 2024.